H ealth Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.

Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the brain, a h allmark of Alzheimer's disease.

Lecanemab is not a cure and cannot rev erse the disease or restore lost memories.

The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country. Current medications mitigate symptoms rather than change the course of the disease.

How well the dru g works and its potential impact on Canada's health-care systems are now considerations for people with the disease, their families, physicians and g

See Full Page